Please wait





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G




Comment for Type of Reporting Person:  Based on 14,524,726 Common Shares outstanding as of 02/17/2026 as reported by Q32 Bio Inc. on 02/17/2026, in its 424B5 Prospectus.


SCHEDULE 13G





SCHEDULE 13G



 
Opaleye Management Inc.
 
Signature:/s/ James Silverman
Name/Title:President
Date:02/20/2026
 
Opaleye, L.P.
 
Signature:/s/ James Silverman
Name/Title:General Partner
Date:02/20/2026
 
James Silverman
 
Signature:/s/ James Silverman
Name/Title:Individually
Date:02/20/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement by and among the reporting persons